Color Vision Impairment Differentiates Alzheimer Dementia From Dementia With Lewy Bodies

2018 ◽  
Vol 31 (2) ◽  
pp. 97-102 ◽  
Author(s):  
Patrick M. Flanigan ◽  
Mitra A. Khosravi ◽  
James B. Leverenz ◽  
Babak Tousi

Objective: Dementia with Lewy bodies (DLB) is frequently misdiagnosed for Alzheimer dementia (AD), especially in its earlier stages. We characterized color vision impairment (CVI) in patients with DLB versus patients with AD to determine its usefulness in improving accuracy of early diagnosis. Methods: We retrospectively reviewed charts of patients with AD, DLB, and patients with mild cognitive impairment suspected to be in the prodromal phase of DLB (pro-DLB) or prodromal phase of AD (pro-AD). All patients underwent an online 15-hue color vision arrangement test. Results: Fifty-two patients were included in this study with a median age of 77 years, of which 44% were female. No significant differences in gender, age, or Montreal Cognitive Assessment existed among patients with AD (n = 15), pro-AD (n = 5), pro-DLB (n = 8), and DLB (n = 24). Of the 52 patients, 4 (2 AD, 1 DLB, and 1 pro-AD) had CVI history from a young age and were excluded from final analyses. New-onset CVI prevalence differed significantly based on diagnosis: patients with pro-AD (20%), patients with AD (15%), patients with pro-DLB (38%), and patients with DLB (78%, P < .001). In a stepwise multivariate logistic regression analysis to determine factors associated with CVI, “diagnosis type” as a binary variable (DLB or pro-DLB vs AD or pro-AD) was the only variable retained in the model (odds ratio = 9.8 [95% CI: 2.3-42.1], P < .001). Conclusions: Color vision impairment in patients with DLB showed a prevalence similar to the core features of DLB (∼80%) and can be supportive to a diagnosis of DLB versus AD. Pending prospective confirmation of our findings, simple online color vision testing could be incorporated into multivariate diagnostic tools to possibly improve accuracy of early diagnosis of DLB.

2006 ◽  
Vol 14 (7S_Part_15) ◽  
pp. P800-P801
Author(s):  
Patrick M. Flanigan ◽  
Mitra A. Khosravi ◽  
Babak Tousi

2018 ◽  
Vol 66 ◽  
pp. 179-184 ◽  
Author(s):  
Claudia Feitosa-Santana ◽  
Givago da Silva Souza ◽  
Esaú Ventura Pupo Sirius ◽  
Anderson Raiol Rodrigues ◽  
Maria Izabel Tentes Cortes ◽  
...  

2015 ◽  
Vol 40 (3-4) ◽  
pp. 186-198 ◽  
Author(s):  
Etsuro Mori ◽  
Manabu Ikeda ◽  
Masaki Nakagawa ◽  
Hideaki Miyagishi ◽  
Hideo Yamaguchi ◽  
...  

Background/Aims: The aim of this study was to clarify the effects of donepezil on extrapyramidal symptoms in patients with dementia with Lewy bodies (DLB). Methods: Using pooled datasets from phase 2 and 3, 12-week randomized, placebo-controlled trials (RCT, n = 281) and 52-week open-label long-term extension trials (OLE, n = 241) of donepezil in DLB, the effects of donepezil on the incidence of extrapyramidal adverse events (AEs) and on the Unified Parkinson's Disease Rating Scale (UPDRS) part III were assessed, and potential baseline factors affecting the AEs were explored. Results: The RCT analysis did not show significant differences between the placebo and active (3, 5, and 10 mg donepezil) groups in extrapyramidal AE incidence (3.8 and 6.5%, p = 0.569) and change in the UPDRS (mean ± SD: -0.2 ± 4.3 and -0.6 ± 6.5, p = 0.562). In the OLE analysis (5 and 10 mg donepezil), the incidence did not increase chronologically; all AEs leading to a dose reduction or discontinuation except one were relieved. The UPDRS was unchanged for 52 weeks. An exploratory multivariate logistic regression analysis of the RCTs revealed that donepezil treatment was not a significant factor affecting the AEs. Baseline severity of parkinsonism was a predisposing factor for worsening of parkinsonism without significant interactions between donepezil and baseline severity. Conclusion: DLB can safely be treated with donepezil without relevant worsening of extrapyramidal symptoms, but treatment requires careful attention to symptom progression when administered to patients with relatively severe parkinsonism.


2008 ◽  
Vol 83 (1) ◽  
pp. 148-149
Author(s):  
Marcelo Fernandes Costa ◽  
Andre Gustavo Fernandes Oliveira ◽  
Claudia Feitosa-Santana ◽  
Mayana Zatz ◽  
Dora Fix Ventura

2018 ◽  
Vol 32 (6) ◽  
pp. 601-606
Author(s):  
Sonia Wagner ◽  
Miguel Rioseco ◽  
Duniel Ortuño ◽  
María F. Cortés ◽  
Carolina Costa

Sign in / Sign up

Export Citation Format

Share Document